BackProtagonist Therapeutics Overview

Protagonist Therapeutics EBIT

EBIT (Earnings Before Interest and Taxes) analysis for PTGX.

Quarterly EBIT

-$4.06M
79% YoY

As of Mar 31, 2026

Annual EBIT (TTM)

-$136.24M
601.68% YoY

Trailing 12 months ending Mar 31, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)